Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 7, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vikram Purohit Downgraded (VTYX) to Hold and Decreased Target to $6 on, Nov 7th, 2023
Vikram Purohit of Morgan Stanley, Downgraded "Ventyx Biosciences, Inc." (VTYX) to Hold and Decreased Target from $46 to $6 on, Nov 7th, 2023.
Vikram has made no other calls on VTYX in the last 4 months.
There are 2 other peers that have a rating on VTYX. Out of the 2 peers that are also analyzing VTYX, 0 agree with Vikram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Vikram
- Simon Flannery of "Morgan Stanley" Maintained at Buy with Increased Target to $46 on, Tuesday, August 29th, 2023
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $62 on, Friday, August 11th, 2023
